Skip to main content

Dynavax (DVAX) Gets a Buy from TD Cowen

Tipranks - Tipranks - Fri Aug 22, 2025

TD Cowen analyst Phil Nadeau maintained a Buy rating on Dynavax today and set a price target of $25.00. The company’s shares opened today at $11.21.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Nadeau is a 4-star analyst with an average return of 4.5% and a 44.06% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Biogen, and Syndax Pharmaceuticals.

In addition to TD Cowen, Dynavax also received a Buy from William Blair’s Matt Phipps in a report issued today. However, on the same day, TR | OpenAI – 4o reiterated a Hold rating on Dynavax (NASDAQ: DVAX).

See the top stocks recommended by analysts >>

Based on Dynavax’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $95.44 million and a net profit of $18.72 million. In comparison, last year the company earned a revenue of $73.8 million and had a net profit of $11.39 million

Read More on DVAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).